Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317756 | 0.86 | ALDH1A1 (0.56) | CYP2C9ALDH1A1ADORA2ASMN1; SMN2RAB9A | |
| SCHEMBL6317135 | 0.86 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2RAB9AKMT2AMAPK1 | |
| SCHEMBL6317147 | 0.86 | ALDH1A1 (0.51) | CYP2C9ALDH1A1ADORA2ASMN1; SMN2RAB9A | |
| SCHEMBL6316915 | 0.86 | ALDH1A1 (0.51) | ALDH1A1ADORA2ASMN1; SMN2RAB9AKMT2A | |
| SCHEMBL6316553 | 0.85 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2RAB9AKMT2ACA2 | |
| SCHEMBL6324303 | 0.83 | NTRK1 (0.48) | ALDH1A1ADORA2ASMN1; SMN2RAB9AKMT2A | |
| SCHEMBL6316081 | 0.83 | ALDH1A1 (0.55) | ALDH1A1ADORA2AKMT2APOLBLMNA | |
| SCHEMBL6317902 | 0.82 | CYP2C9 (0.54) | CYP2C9ALDH1A1CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL6315873 | 0.82 | BACE1 (0.46) | ALDH1A1ADORA2ACHRNB2CHRNA4BACE1 | |
| SCHEMBL6315811 | 0.81 | TSHR (0.56) | CYP2C9ALDH1A1SMN1; SMN2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | CYP2C9 4466/4885ALDH1A1 4444/4885ADORA2A 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.